Protein Interaction Domain Mapping for the Selection of Validated Targets and Lead Compounds in the Anti-Infectious Area

Legrain, P.; Strosberg, D.
June 2002
Current Pharmaceutical Design;Jun2002, Vol. 8 Issue 13, p1189
Academic Journal
Despite considerable progress in the analysis of microbial genomes, the number of validated targets suitable for the development of drugs acting on agents causing infectious diseases remains modest. The diversity of new chemical entities specific for such targets has almost not increased over the last years, while resistance to antiinfectious drugs has, in contrast, become a real threat in certain surroundings. New strategies are thus needed for selecting novel validated targets. We discuss here a combined approach which uses protein interaction mapping as the basic strategy to identify interacting domains which then serve to validate newly identified targets. The interactome of Helicobacter pylori is used as model to successively describe high-throughput protein interaction mapping, use of the H. pylori data to predict the interactome from other bacteria, analysis of interacting domains, and evaluation of the capacity of one such domain to block synthesis of flagella. The general applicability of this approach to target identification and validation, and to development of novel compounds is also discussed.


Related Articles

  • A Proline-Hinge Alters the Characteristics of the Amphipathic α-helical AMPs. Lee, Jong Kook; Gopal, Ramamourthy; Park, Seong-Cheol; Ko, Hyun Sook; Kim, Yangmee; Hahm, Kyung-Soo; Park, Yoonkyung // PLoS ONE;Jul2013, Vol. 8 Issue 7, p1 

    HP (2–20) is a 19-aa, amphipathic, α-helical peptide with antimicrobial properties that was derived from the N-terminus of Helicobacter pylori ribosomal protein L1. We previously showed that increasing the net hydrophobicity of HP (2–20) by substituting Trp for Gln17 and Asp19...

  • A simple and cost-effective method for rapid purification of alkyl hydroperoxide reductase (AhpC) from Helicobacter pylori and its antibody production. T., Mohammadian; M., Doosti; M., Paknejad; F., Siavoshi; S., Massarrat // DARU;2008, Vol. 16 Issue 3, p174 

    Background and the purpose of the study: Helicobacter pylori express abundant amounts of AhpC enzyme that functions to reduce organic hydroperoxides (ROOH) into the corresponding non-toxic alcohols (ROH). This conserved antigen has been earlier described as specific and unique for H. pylori and...

  • CHEMEQ DRUG ACTIVE AGAINST GASTRIC ULCER GERM.  // Worldwide Biotech;Apr2003, Vol. 15 Issue 4, p2 

    Focuses on the development of an antimicrobial drug that kills a strain of the gastric ulcer germ, Helicobacter pylori which is resistant to antibiotics, by pharmaceutical company Chemeq Ltd, as of April 2003.

  • Yearly prevalence of primary metrodinazole and clarithromycin resistance of H. pylori: a prospective study in consecutive out-patients (Brussels 1995-2001). Burett, A.C.; Vandenborre, C.; Goutier, S. // Gut;Sep2002 Supplement 2, Vol. 51, pA92 

    Aim of the Study: The main determinants of anti-H. pylori (Hp) treatment success are patient compliance and the antimicrobial susceptibility of the infecting strains. The aim of this study is to follow the local prevalence of primary resistance to M and C in Hp isolates in Brussels. Method: All...

  • Traditional and Non-Traditional Antimicrobial Agents for H. Pylori Infection. Kato, Mototsugu; Hokari, Kaku; Kagaya, Hideotoshi; Takeda, Hiroshi; Sugiyama, Toshiro; Asaka, Masahiro // Current Pharmaceutical Design;Oct2000, Vol. 6 Issue 15, p1575 

    Triple therapy with a proton pump inhibitor plus two antibiotics is recently standard regimen for treatment of H. pylori infection. However, the agents that are used for H. pylori eardication are not always limited to drugs whose primary use is as an antimicrobial agent. Anti-H. pylori activity...

  • Past Antibiotic Use Affects Resistance and Outcomes of Helicobacter pylori Infection. Mcmahon, B.J.; Hennessy, T.W.; Bensler, J.M.; Bruden, D.L.; Parkinson, A.J.; Morris, J.M.; Reasonover, A.L.; Huriburt, D.A.; Bruce, M.G.; Sacco, F.; Butler, J.C. // Annals of Internal Medicine;9/16/2003, Vol. 139 Issue 6, pI10 

    Helicobacter pylori is a common type of bacteria that usually infects people during their childhoods. In most cases, the infection does not cause problems. However, some people with H. pylori infection get inflammation or ulcers in the stomach or upper intestine. Doctors treat inflammation and...

  • A Rigidity-Enhanced Antimicrobial Activity: A Case for Linear Cationic α-Helical Peptide HP(2-20) and Its Four Analogues. Li Liu; Ying Fang; Qingsheng Huang; Jianhua Wu // PLoS ONE;2011, Vol. 6 Issue 1, p1 

    Linear cationic a-helical antimicrobial peptides are referred to as one of the most likely substitutes for common antibiotics, due to their relatively simple structures (#40 residues) and various antimicrobial activities against a wide range of pathogens. Of those, HP(2-20) was isolated from...

  • Reality and false premises of antimicrobial susceptibility testing for Helicobacter pylori. Miwa, Hiroto; Sato, Nobuhiro // Journal of Gastroenterology;2003, Vol. 38 Issue 5, p519 

    Focuses on the antimicrobial susceptibility shown by the bacteria Helicobacter pylori. Resistance shown by the pylori strains towards clarithomycin; Relationship of metronidazole-resistant strains with the treatment failures; Influence of CAM resistance on the efficacy of proton pump inhibitor...

  • Antibiotic Treatment Strategies for Helicobacter pylori Infection. Campo, S. M. A.; Zullo, A.; Hassan, C.; Morini, S. // Recent Patents on Anti-Infective Drug Discovery;Jan2007, Vol. 2 Issue 1, p11 

    In the third decade of the Helicobacter pylori era several informations are available on its pathogenetic mechanisms, as well as on therapeutic approaches. A 7-14 day triple or quadruple regimens (proton pump inhibitor together with 2 antibiotics) are currently suggested as first-line treatment,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics